DF Dent & Co. Inc. Trims Stock Position in Repligen Co. (NASDAQ:RGEN)

DF Dent & Co. Inc. cut its stake in Repligen Co. (NASDAQ:RGEN) by 4.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 563,280 shares of the biotechnology company’s stock after selling 27,041 shares during the quarter. DF Dent & Co. Inc. owned about 1.01% of Repligen worth $81,079,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of RGEN. Signaturefd LLC raised its stake in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. purchased a new position in shares of Repligen during the 4th quarter worth approximately $29,000. Resources Management Corp CT ADV bought a new position in shares of Repligen in the 3rd quarter worth approximately $37,000. Quarry LP lifted its stake in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares during the period. Finally, UMB Bank n.a. boosted its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $130.92 on Thursday. The business has a 50-day simple moving average of $152.03 and a two-hundred day simple moving average of $147.88. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of -256.71, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Royal Bank of Canada boosted their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Finally, Evercore ISI began coverage on Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $178.64.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.